Five years ago, Ward Thrasher was diagnosed with Stage 4 colon cancer. In December 2022 he was the first person in the world to be given Dragonfly’s EGFR TriNKET. It’s the fifth time Mr. Thrasher has participated in a clinical trial; he received the lowest starting dose of our EGFR-targeting TriNKET, and is experiencing good quality of life, no side effects, and some tumor shrinkage. Our hope for Mr. Thrasher and other patients on our EGFR trial as we approach our targeted dose is to see ever-increasing patient benefits. We admire and thank patients like Mr. Thrasher for their courage in participating in clinical trials critical to advancing life-saving therapies. https://lnkd.in/eNzf7jHt
Thomas Reidy
1y
Thank you, Mr. Thrasher, for participating in this clinical trial. Also, thank you to the team at Dragonfly for creating this novel drug.
THIS is what it's all about. 👏
eventually this hard work translates to lives saved
Wow smart and brave guy, you can tell just from the article!
Bo Wang
1y
Thanks for sharing. It’s inspiring. Bonnie from W.R.Grace
Thank you Mr. Thrasher. Often, clinical trials depend upon people like you.
Bo Wang
1y
Thanks for sharing! Bonnie from W.R.Grace
Thank you also to Lifespan and so many other cancer centers for shepherding our Dragonfly invented & developed drugs into the clinic to benefit patients, and of course all the innovative, hardworking Dragonflyers!